[2-(methylamino)pyridin-3-yl]methanol | CAS:32399-12-5

We serve [2-(methylamino)pyridin-3-yl]methanol CAS:32399-12-5 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
[2-(methylamino)pyridin-3-yl]methanol

Chemical Name:[2-(methylamino)pyridin-3-yl]methanol
CAS.NO:32399-12-5
Synonyms:[2-(methylamino)pyridin-3-yl]methanol
2-(N-Methylamino)-3-hydroxymethylpyridine
[2-(Methylamino)-3-pyridinyl]methanol
 
Physical and Chemical Properties:
Density 1.2±0.1 g/cm3
Boiling Point 312.2±32.0 °C at 760 mmHg
Molecular Formula C7H10N2O
Molecular Weight 138.167
Flash Point 142.6±25.1 °C
 
Specification:
Appearance:Off-white to yellow powde
Assay:≥98.0%
Moisture:≤1.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Isavuconazole(CAS:241479-67-4).



Contact us for information like [2-(methylamino)pyridin-3-yl]methanol chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,[2-(Methylamino)-3-pyridinyl]methanol physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,[2-(methylamino)pyridin-3-yl]methanol Use and application,2-(N-Methylamino)-3-hydroxymethylpyridine technical grade,usp/ep/jp grade.


Related News: As the global generic drug market booms and the international API industry accelerates its transfer to developing countries, China and India rely on cost advantages to rapidly grow into major API producers and exporters.Sulfur dichloride manufacturer This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.4-Chlorobutyronitrile supplier This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.5-Bromo-1-pentene vendor “We are grateful that this young man is recovering and sought medical attention immediately,’’ said Massachusetts Public Health Commissioner Monica Bharel, MD. MPH. “Massachusetts has been preparing for a possible case of this new coronavirus, and we were fortunate that astute clinicians took appropriate action quickly. Again, the risk to the public from the 2019 novel coronavirus remains low in Massachusetts.”New Zealand on Sunday became the latest country to impose restrictions on travelers from mainland China, saying it would deny entry to visitors departing from or transiting through the mainland for two weeks starting on Monday.